In post-myocardial infarction patients with overweight or obesity and HbA1c 6.0-6.4%, the estimated 5-year NNT with semaglutide to prevent one case of type 2 diabetes was 2.7, extrapolated from SELECT.
In plain wordsUsing SELECT trial results, researchers estimated that 2.7 such patients would need semaglutide to prevent one diabetes case. Nobody here took it.
- Peptide
- Semaglutide
- Outcome
- Not applicableEstimated 5-year NNT with semaglutide to prevent type 2 diabetes (HbA1c 6.0-6.4% subgroup)
- Study
n: not reported in source
- Outcome group
- Glycemic control · Metabolic and weight
Measurements
- NNT5
- 2.7 patients
- prediabetes 6.0-6.4% subgroup
Source sentences
the estimated NNT5 with semaglutide to prevent one case of type 2 diabetes was 2.7 in this subgroup.
1 context sentence(design, population, supporting numbers)
We included patients registered in the Western Denmark Heart Registry with first-time myocardial infarction and body mass index (BMI) ≥ 27 kg/m2 without diabetes, thus meeting the eligibility criteria of the SELECT trial.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.